Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr McDermott on the Ongoing LITESPARK-024 Trial in Pretreated Advanced RCC

July 14th 2023

David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14th 2023

Neoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

July 14th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

July 14th 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Imaging Mass Cytometry May Identify Therapeutic Targets in ccRCC

July 13th 2023

The tumor-immune evasion cell networks in clear cell renal cell carcinoma may be captured and classified using imaging mass cytometry, an orthogonal approach with the potential for increased cost-efffectiveness and accuracy compared with single-cell RNA sequencing.

China’s NMPA Accepts sNDA for Frontline Toripalimab Plus Axitinib in Metastatic RCC

July 12th 2023

China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab plus for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma

Negative Survival Data From CONTACT-03 Call ICI Rechallenge in Advanced RCC Into Question

July 11th 2023

Toni K. Choueiri, MD, highlights findings from the CONTACT-03 trial and their clinical significance, as well as the need for continued investigation of PD-1 inhibitor rechallenge despite the negative trial results with cabozantinib and atezolizumab.

Rationale Behind Discontinuing IO Therapy in Clear Cell RCC

July 10th 2023

Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.

Selecting Therapy for a Real-World Patient With Clear Cell RCC

July 10th 2023

Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.

Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC

July 7th 2023

Thomas Hutson, DO, PharmD, expands on previously reported findings from the CLEAR study, details updated data from the final OS analysis, and emphasizes how these results support the use of this regimen as a mainstay treatment option in the frontline setting for patients with advanced RCC.

Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC

July 3rd 2023

Panelists consider best practices in dosing while managing patients on first-line therapy for advanced clear cell renal cell carcinoma.

Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies

July 3rd 2023

Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.

Dr Vaishampayan on Cabozantinib Plus Atezolizumab in RCC

June 29th 2023

Ulka Nitin Vaishampayan, MBBS, discusses findings from the phase 3 CONTACT-03 trial in patients with renal cell carcinoma.

Dr Sonpavde on the Potential Impact of the THOR Study in FGFR2/3-Altered Urothelial Carcinoma

June 29th 2023

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

Dr Choueiri on the Investigation of ICI Continuation in Advanced RCC

June 28th 2023

Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.

Further Research Needed to Inform the Management of Post-Chemo Residual Nonretroperitoneal Disease in Testicular Cancer

June 26th 2023

Jennifer M. King, MD, expands on the design and methodology of a retrospective study of teratoma in residual nonretroperitoneal disease post-chemotherapy and key findings regarding the correlation between teratoma in the primary tumor and rates of post-chemotherapy teratoma in residual non–nonretroperitoneal disease.

Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC

June 26th 2023

A brief discussion on the patient and disease characteristics that help to inform selection of best therapy for patients with advanced clear cell renal cell carcinoma.

Overview of First-Line Combination Therapy in Advanced Clear Cell RCC

June 26th 2023

Key opinion leaders on renal cell carcinoma management review first-line treatment options in the advanced clear cell disease space.

Dr Vaishampayan on the Impact of TKI Combination Therapies in the Treatment of RCC

June 23rd 2023

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Determining the Optimal Use of Adjuvant Immunotherapy in Renal Cell Carcinoma

June 19th 2023

Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.